R01CA96920/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2006	1
2007	1
2008	1
2009	1
2025	0

Page 1

Involvement of hepcidin in the anemia of multiple myeloma.

Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, Ganz T, Lichtenstein A. Sharma S, et al. Clin Cancer Res. 2008 Jun 1;14(11):3262-7. doi: 10.1158/1078-0432.CCR-07-4153. Clin Cancer Res. 2008. PMID: 18519751

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.

Frost P, Shi Y, Hoang B, Lichtenstein A. Frost P, et al. Oncogene. 2007 Apr 5;26(16):2255-62. doi: 10.1038/sj.onc.1210019. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016437

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A. Frost P, et al. Mol Cancer Ther. 2009 Jan;8(1):83-93. doi: 10.1158/1535-7163.MCT-08-0254. Mol Cancer Ther. 2009. PMID: 19139116 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year